GlassScriptPhysician profile
Amrit K Grewal
NPI 1154382331
$1,765.81
in general payments reported to CMS, 2019-2025
11 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.40 · 2022: $300 · 2023: $278 · 2024: $1,051 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.18 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.28 | 2022-2024 | |
| Boston Scientific Corporation | $316.10 | 2022-2024 | |
| Abbott Laboratories | $268.90 | 2024-2025 | Infinity |
| E.R. Squibb & Sons, L.L.C. | $237.27 | 2022-2024 | Zeposia |
| Insightec,INC | $145.51 | 2024 | Exablate |
| Medtronic, INC. | $130.96 | 2024 | Percept PC Brainsense |
| Eisai INC. | $118.39 | 2024 | |
| Amylyx Pharmaceuticals, INC. | $116.65 | 2023 | Relyvrio |
| Alexion Pharmaceuticals, INC. | $34.12 | 2023 | Ultomiris |
| Amneal Pharmaceuticals LLC | $31.23 | 2024 | Rytary, Crexont |
| Grifols USA, LLC | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.